Molecular Formula | C5H7ClN2O3 |
Molar Mass | 178.57 |
Density | 1.85±0.1 g/cm3(Predicted) |
Melting Point | >200°C (dec.) |
Boling Point | 341.6±48.0 °C(Predicted) |
Water Solubility | Soluble in water at 10mg/ml with warming |
Solubility | H2O: soluble10mg/mL (warmed) |
Appearance | White solid. |
Color | white to beige |
pKa | 2.02±0.10(Predicted) |
Storage Condition | 2-8°C |
Stability | Hygroscopic |
In vitro study | Acivicin (AT-125; 0.1-50 μM; 5 days) has an IC 50 of 0.7 μM in human HepG2 cells. |
In vivo study | Acivicin (AT-125; 5 mg/kg; IP; twice weekly) reduces urinary γ-GT by 70-78%. Animal Model: Male pigmented Long-Evans rats weighed between 250 g and 300 g exposed to Toluene Dosage: 5 mg/kg Administration: IP; twice weekly (monday and wednesday) Result: Reduced urinary γ-GT by 70-78%. |
Hazard Symbols | Xn - Harmful![]() |
Risk Codes | 20/21/22 - Harmful by inhalation, in contact with skin and if swallowed. |
Safety Description | 36 - Wear suitable protective clothing. |
UN IDs | 3172 |
WGK Germany | 3 |
RTECS | NY2103000 |
Hazard Class | 6.1(b) |
Packing Group | III |
Biological activity | Acivicin (AT-125) is a natural product produced by Streptomyces suis and is a γ-glutamyl transpeptidase (GGT) inhibitor. Acivicin can penetrate the blood-brain barrier and have anti-cancer and anti-parasitic properties. |
Target | γ-glutamyl transpeptidase |
in vitro study | Acivicin (AT-125; 0.1-50 μM; 5 days) has an IC 50 of 0.7 μM in human HepG2 cells. |
in vivo study | Acivicin (AT-125; 5 mg/kg; IP; Wice weekly) reduces urinary γ-GT by 70-78%. Animal Model: Male pigmented Long-Evans rats weighed between 250 g and 300 g exposed to Toluene Dosage: 5 mg/kg Administration: IP; Wice weekly (Monday and Wednesday) Result: reduced urinary γ-GT by 70-78%. |
Animal Model: | Male pigmented Long-Evans rats weighed between 250 g and 300 g exposed to Toluene |
Dosage: | 5 mg/kg |
Administration: | IP; twice weekly (monday and wednesday) |
Result: | Reduced urinary γ-GT by 70-78%. |